Ainos, Inc. AIMD
At closeNov 4, 2026, 7:27 PM EST
After hours · Nov 4, 7:27 PM ET
- YTD
- -55.46%
- 1 year
- -77.73%
- Market cap
- 5.39M
- Revenue (ttm)
- 40.63K
- EPS (ttm)
- -2.87
- Shares out
- 14.54M
- YTD return
- -55.46%
- 1-year return
- -77.73%
- Volume
- 469.02K
- Avg volume
- 133.19K
- Open
- 0.635
- Previous close
- 0.62
- Day's range
- 0.63 – 0.868
- 52-week range
- 0.56 – 3.88
- Beta
- 1.41
5D -0.0896 (-10.93%)
Key statistics
- Enterprise value
- 13.36M
- PEG ratio
- 0.00
- Price / sales
- 167.25
- Price / book
- 0.36
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 621.86K
- Total cash
- 5.16M
- Total debt
- 12.27M
- Return on equity
- -70.60%
- Short % of float
- 1.44%
- 50-day average
- 0.4748
- 200-day average
- 0.74847
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | 0.00 | -0.33 | — | — |
| Aug 5, 2024 | Jun 1, 2024 | 0.00 | -0.49 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.57 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.75 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -0.60 | — | — |
| May 12, 2023 | Mar 1, 2023 | 0.00 | -0.65 | — | — |
About Ainos, Inc.
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- ainos.com
News
12 Information Technology Stocks Moving In Wednesday's After-Market Session 
Ainos Announces AI Nose Platform Hits Over 3B Chemical Data Points 
12 Information Technology Stocks Moving In Thursday's After-Market Session 
Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket 
Ainos Completes Required Data Delivery And Technology Transfer Under Its VELDONA License Deal For $600K Initial License Payment 
Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment 
Ainos Completes Delivery of 1,400 AI Nose Systems to ASE Under $2.1 Million, Three-Year Contract 
Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence 
Ainos, Inc. (NASDAQ:AIMD) Shares Shorted: Short Interest Up 172.6% in September 
12 Information Technology Stocks Moving In Thursday's Pre-Market Session
Your note
Sign in to keep a note on AIMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHANG WEN-HAN | Director | Conversion of Exercise of derivative security | Jan 30, 2024 | 106,265 |
| CHIANG YAO-CHUNG | Director | Conversion of Exercise of derivative security | Jan 30, 2024 | 54,932 |
| LEE HSIN LIANG CHRISTOPHER | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 25, 2024 | 22,376 |
| LEE TING CHUAN | Director | Conversion of Exercise of derivative security | Nov 25, 2024 | 327,432 |
| LIN LAWRENCE K | Officer | Conversion of Exercise of derivative security | Feb 15, 2024 | 11,260 |
| SUNG MENG-LIN | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 15, 2024 | 61,050 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.48% | 67,007 | 31.31K | Sep 29, 2024 |
| Virtu Financial LLC | 0.33% | 45,221 | 21.13K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.17% | 23,321 | 10.90K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.17% | 24,058 | 11.24K | Sep 29, 2024 |
| Blackrock Inc. | 0.11% | 15,325 | 7.16K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.06% | 8,763 | 4.09K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.14% | 19,951 | 9.32K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.02% | 3,305 | 1.54K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.01% | 1,966 | 918 | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,980 | 925 | Oct 30, 2024 |